GlaxoSmithKline, development phase drugs

Class 1 drugs represent a subset of drugs that is decreasing with time If the orally administered immediate release products in the List of Essential Medicines of the World Health Organization (WHO) are considered, approximately 30% can be considered as class 1 drugs (97,98). However, the proportion of class 1 compounds in the development phase for oral immediate-release formulations at AstraZeneca was less than 10% in 2001 (99), and is sHghtly less than 20% at GlaxoSmithKline (100). 

---